A new analysis in Cell Death Discovery highlights why promising cell therapies can stumble at the regulatory gate, tracing technical and documentation failures behind several unsuccessful IND and BLA/NDA outcomes. Led by Han, Xie, Shi and colleagues, the work draws attention to a recurring mismatch: the biological rationale may look compelling, but the product is not “manufacturable” in the way regulators require.
The study argues that many submissions fail not because the science is fundamentally wrong, but because critical quality attributes are not controlled with sufficient evidence. In cell therapy programs, the therapeutic effect depends on subtle variables—such as cell identity, viability, potency, purity, and the distribution of functional states—yet these properties must be demonstrated through rigorous characterization and linked to clinical performance.
A central theme is comparability. As manufacturing processes evolve—from scale-up to media changes to cryopreservation workflows—developers must prove that the final product remains equivalent across batches and over time. When analytical methods cannot reliably detect meaningful differences, regulators have limited confidence that the therapy used in trials matches the therapy intended for approval.
The authors also emphasize potency assays, which remain a frequent weak point. Functional readouts must be specific, validated, and suitable for release decisions. If potency measures are unstable or poorly correlated with clinical outcomes, the submission can appear scientifically incomplete, even when early efficacy signals exist.
Regulatory success, the paper suggests, is inseparable from documentation discipline. Sponsors are expected to provide transparent manufacturing records, well-defined release criteria, and statistically grounded plans for stability and variability. Gaps in method performance, acceptance criteria, or failure investigations can undermine the overall credibility of the quality system.
The article further notes that immunogenicity and safety characterization must be supported by product-relevant testing strategies. For complex cellular products, the boundary between “process-related” and “product-related” risk is not always clear, and insufficient risk assessment can trigger regulatory concern.
Overall, the authors frame their review as a set of practical lessons: treat regulatory filing as an extension of manufacturing and analytical validation, not a final administrative step. For investors and developers, the message is blunt—regulatory readiness must be built into development plans from the start.
The work is a reminder that in viral science news terms, the “biology” is only half the story; the other half is the evidence chain that connects cells, assays, batches, and patients with auditable consistency.
Subject of Research: Cell therapy regulatory and technical challenges affecting IND and BLA/NDA approvals
Article Title: Technical and regulatory challenges in cell therapy products: lessons from unsuccessful IND and BLA/NDA approvals.
Article References: Han, D., Xie, J., Shi, Y. et al. Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03258-w
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03258-w
Keywords:
Tags: cell therapy product characterizationcell therapy regulatory approval challengeschallenges in demonstrating product equivalencecomparability and process consistency in cell manufacturingcritical quality attribute control in cell therapyimpact of manufacturing variability on cell therapy approvalIND and BLA submission failuresmanufacturing process validation in cell therapypotency assay validation in regenerative medicinequality attributes for cell therapiesregulatory requirements for cell therapy productstechnical documentation failures in cell therapy approvals
